China-based drug maker Innovent Biologics has revealed that China’s National Medical Products Administration has approved its application to test a combination therapy comprising a proposed biosimilar bevacizumab product, IBI305, plus sintilimab, an anti–programmed cell death protein 1 (PD-1) monoclonal antibody.
China-based drug maker Innovent Biologics has revealed that China’s National Medical Products Administration has approved its application to test a combination therapy comprising a proposed biosimilar bevacizumab product, IBI305, plus sintilimab, an anti—programmed cell death protein 1 (PD-1) monoclonal antibody.
Innovent’s clinical trials for the combination will include patients with non—small cell lung cancer (NSCLC) and hepatocellular carcinoma.
According to Innovent, the relationship between vascular endothelial growth factor—targeted by bevacizumab—and tumor-induced immunosuppression driven by PD-1 is a promising target. Abnormal tumor-induced angiogenesis appears to limit the therapeutic effect of anti—PD-1 antibodies and other immunotherapy products, and Innovent hopes the combination of sintilimab and biosimilarbevacizumab will be better able to control tumor growth by stimulating the immune system with an anti–PD-1 agent and blocking angiogenesis with bevacizumab.
Innovent says that has completed bioequivalence studies for IBI305 in healthy volunteers, as well as a randomized, double-blind, multicenter phase 3 study in patients with NSCLC. The phase 3 study compared IBI305 with the reference Avastin.
Sintilimab, which Innovent has developed jointly with Eli Lilly, has already shown promising results as a first-line treatment for patients with NSCLC; in September 2018, Innovent presented data on sintilimab in combination with pemetrexed and cisplatin in patients with nonsquamous NSCLC during the annual meeting of the Chinese Society of Clinical Oncology. The combination, said Innovent’s researchers, demonstrated and objective response rate of 68.4%, based on 19 patients.
"It was encouraging to learn the outstanding efficacy of sintilimab in combination with pemetrexed and cisplatin for first line treatment of NSCLC. I hope to see the approval of sintilimab for first-line treatment of NSCLC in the near future, allowing more patients suffering from NSCLC to benefit from it," Caicun Zhou, MD, PhD, of the Shanghai Pulmonary Hospital, said in a statement.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.